Analysis of the pediatric population of cystic fibrosis for the improvement Of pharmaceutical care

• Autores: Juan Carlos del Río Valencia, Rocío Tamayo Bermejo, Carmen Gallego Fernández
• Localización: European journal of clinical pharmacy: atención farmacéutica, ISSN 2385-409X, Vol. 19, Nº. 3, 2017, págs. 164-169
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Introduction. Patients with cystic fibrosis are chronic patients so due to their prevalence, the study of their characteristics deserves special dedication to respond to their needs. The intervention of the pharmacist in the care of patients responds to the need to optimize a pharmacological treatment which is complex and it is administered through different ways and with a high risk of causing adverse effects and interactions. The hospital pharmacist has identified the chronic patient as the core of the new care model and he is working on models that allow us to define, homogenize and stratify in order to prioritize pharmaceutical care to these patients. The aim is to analyze the pediatric population of cystic fibrosis treated to optimize the pharmaceutical care provided. Method. Cross-sectional study in which pediatric patients affected by fibrosis are analyzed. The Model of Selection and Pharmaceutical Care for Pediatric Chronic Patients of the Spanish Society of Hospital Pharmacy (SEFH) is used for the development of the study. ; Results. We analyzed 33 pediatric patients affected by cystic fibrosis between the ages of 4 months and 16 years, with 63.63% being men. Patients are stratified into four levels: 9 patients (27.3%) belong to risk level 1,14 (42.4%) to level 2,9 (27.3%) to level 3 and 1 patient (3%) to level 4. Also notable is that 32 patients (96.9%) suffer multi-pathological processes, 31 patients (93.9%) are polymedicated, 100% have complex administration patterns and 100% use high-risk medicines. Conclusions. Knowing the characteristics and needs of a population will allow the development of interventions that may contribute to improve pharmacotherapy and the use of chronic pediatric patient's medicines